Physician profile
Scott S Chae
NPI 1851409650
$16,105.71
in general payments reported to CMS, 2019-2025
29 companies · $2,742 in 2025
The $2,742 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,851 · 2020: $898 · 2021: $4,748 · 2022: $1,648 · 2023: $1,983 · 2024: $2,235 · 2025: $2,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,823 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,822.70 |
| Education | $137.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,943.39 | 2019-2025 | Vemlidy, Epclusa |
| Abbvie INC. | $3,555.59 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,269.77 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Fujifilm Healthcare Americas Corporation | $909.29 | 2021 | |
| Redhill Biopharma INC. | $662.40 | 2020-2025 | Talicia, Aemcolo, Movantik |
| Janssen Biotech, INC. | $660.82 | 2021-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $635.04 | 2024-2025 | Voquezna |
| Pfizer INC. | $597.07 | 2019-2025 | |
| Daiichi Sankyo INC. | $583.65 | 2019-2024 | Injectafer |
| Madrigal Pharmaceuticals | $492.68 | 2024-2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $452.92 | 2019-2025 | Ocaliva |
| Celgene Corporation | $388.99 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $257.56 | 2023-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $255.08 | 2019-2025 | Entyvio |
| Vivus LLC | $237.78 | 2022-2025 | Qsymia, Pancreaze |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $231.47 | 2021-2023 | Sucraid |
| Allergan, INC. | $184.00 | 2019-2020 | |
| Echosens North America, INC. | $168.01 | 2019-2023 | Fibroscan |
| Pharmacosmos Therapeutics INC. | $125.00 | 2025 | Monoferric |
| Medtronic, INC. | $123.30 | 2023 | Endoflip |
| Nestle Healthcare Nutrition INC. | $97.39 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $96.13 | 2019-2023 | Linzess |
| Ipsen Biopharmaceuticals, INC | $48.95 | 2024-2025 | Bylvay, Iqirvo |
| Merck Sharp & Dohme LLC | $43.36 | 2023 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $22.79 | 2022 | |
| Shionogi INC | $22.68 | 2019 | |
| Celltrion USA INC. | $16.07 | 2024 | Zymfentra |
| Braintree Laboratories, INC. | $14.05 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Chae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.